N-(4-chlorophenyl)-N',N'-diethyl-1,2-ethanediamine | 5427-35-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-(4-chlorophenyl)-N',N'-diethyl-1,2-ethanediamine
• 英文别名: N,N-diethyl-N'-(4-chloro-phenyl)-ethylenediamine；N,N-Diaethyl-N'-(4-chlor-phenyl)-aethylendiamin；4-chloro-N-(2-(diethylamino)ethyl)benzeneamine；4-Chloro-N-[2-(diethylamino)ethyl]aniline；N-(4-chlorophenyl)-N',N'-diethylethane-1,2-diamine
• CAS: 5427-35-0
• 化学式: C₁₂H₁₉ClN₂
• 分子量: 226.749
• InChiKey: NCAAIVMJHDTUNT-UHFFFAOYSA-N

物化性质

• 沸点：
  165-167 °C(Press: 12 Torr)
• 密度：
  1.076±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2921590090

反应信息

• 作为反应物：
  描述：

  N-(4-chlorophenyl)-N',N'-diethyl-1,2-ethanediamine 、 4-<(methylsulfonyl)amino>benzoyl chloride 以 四氢呋喃 为溶剂， 反应 17.0h， 生成 N-(4-chlorophenyl)-N-<2-(diethylamino)ethyl>-4-<(methylsulfonyl)amino>benzamide
  参考文献：
  名称：

  Synthesis and cardiac electrophysiological activity of aryl-substituted derivatives of the class III antiarrhythmic agent sematilide. Potential class I/III agents

  摘要：

  Twelve novel derivatives of the selective class III antiarrhythmic agent sematilide were prepared in an attempt to incorporate both class I and class III electrophysiological properties into a single molecule. Electrophysiological activity was determined by standard microelectrode techniques in canine cardiac Purkinje fibers. Initial assessment of class I efficacy was carried out in a ouabain-induced arrhythmia model in guinea pigs. All of the compounds prolonged action potential duration in Purkinje fibers (class III activity), and three were active against ouabain-induced arrhythmias (class I activity). Selected compounds were evaluated further in dogs for efficacy against arrhythmias occurring 24 h following coronary ligation (automatic arrhythmias) and induced by using programmed electrical stimulation techniques (reentrant arrhythmias). The most effective compounds from the series are 3g and -j, which were effective in both canine models. Molecular modeling and structure-activity relationships are discussed.

  DOI：

  10.1021/jm00164a025
• 作为产物：
  描述：

  2-二乙氨基-1-溴乙烷氢溴酸盐 、 对氯苯胺 在 N,N-二异丙基乙胺 、 碳酸氢钠 作用下， 以 甲苯 、 水 、 乙酸乙酯 为溶剂， 反应 5.0h， 生成 N-(4-chlorophenyl)-N',N'-diethyl-1,2-ethanediamine
  参考文献：
  名称：

  [EN] PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS
  [FR] PYRIMIDYL CYCLOPENTANES UTILSÉS COMME INHIBITEURS DE LA PROTÉINE KINASE AKT

  摘要：

  本发明提供了一种I式化合物，包括互变异构体、已分离的对映体、非对映异构体、溶剂合物、代谢物、盐和其药学上可接受的前药。还提供了使用该发明的化合物作为AKT蛋白激酶抑制剂和用于治疗癌症等高增殖性疾病的方法。

  公开号：

  WO2009006569A1

文献信息

• [1H-Pyrazolo[3, 4-D]Pyrimidin-4-Yl]-Piperidine or -Piperazine Compounds as Serine-Theoronine Kinase Modulators (P70s6k, Atk1 and Atk2) for the Treatment of Immunological, Inflammatory and Proliferative Diseases
  申请人：Rice Ken

  公开号：US20080188482A1

  公开（公告）日：2008-08-07

  The invention provides compounds of formula (I) and methods for inhibition of kinases, more specifically p70S6 kinases, and more preferably p70S6, Akt-1 and Akt-2 kinases. The invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration, chemoinvasion and metabolism. Compounds of the invention inhibit, regulate and/or modulate kinase receptor signal transduction pathways related to the changes in cellular activities as mentioned above, and the invention includes compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions.

  本发明提供了式（I）的化合物和抑制激酶的方法，更具体地是p70S6激酶，更优选的是p70S6，Akt-1和Akt-2激酶的抑制剂。本发明提供了用于调节蛋白激酶酶活性以调节细胞活动（如增殖，分化，程序性细胞死亡，迁移，化学入侵和代谢）的化合物。本发明的化合物抑制，调节和/或调节与上述细胞活动变化相关的激酶受体信号转导途径，本发明包括含有这些化合物的组合物和使用它们治疗依赖于激酶的疾病和情况的方法。
• PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS
  申请人：Bencsik Josef R.

  公开号：US20110160221A1

  公开（公告）日：2011-06-30

  The present invention provides compounds of Formula I, including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.

  本发明提供了式I的化合物，包括互变异构体、已分离的对映异构体、二对映异构体、溶剂化物、代谢物、盐和其药学上可接受的前药。本发明还提供了使用这些化合物作为AKT蛋白激酶抑制剂和治疗癌症等增生性疾病的方法。
• Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
  申请人：Bencsik Josef R.

  公开号：US08377937B2

  公开（公告）日：2013-02-19

  The present invention provides compounds of Formula I, including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.

  本发明提供了I式化合物，包括互变异构体、已分离的对映体、非对映异构体、溶剂化物、代谢产物、盐以及其药学上可接受的前药。同时，还提供了使用本发明的化合物作为AKT蛋白激酶抑制剂以及用于治疗高增殖性疾病，如癌症的方法。
• Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
  申请人：Array BioPharma Inc.

  公开号：US08846683B2

  公开（公告）日：2014-09-30

  The present invention provides compounds of Formula I, including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.

  本发明提供了I式化合物，包括互变异构体、分离的对映体、非同构体、溶剂化物、代谢物、盐和其药学上可接受的前药。同时，本发明提供使用这些化合物作为AKT蛋白激酶抑制剂以及治疗癌症等高增殖性疾病的方法。
• Some N-(2-Diethylaminoethyl)-anilines¹
  作者：Mark A. Stahmann、Arthur C. Cope

  DOI：10.1021/ja01216a017

  日期：1946.12